Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Betaseron · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Betaseron (Interferon beta-1b, BAY86-5046) | DRUG | 250 mcg |
Inclusion Criteria: Diagnosis of RRMS as defined by any of the following McDonald diagnostic criteria (McDonald et al 2001; see Appendix 16.1.1 \[(Protocol Appendix 5\]): * Two relapses and objective clinical evidence (history or present) of at least 2 lesions * Two relapses and objective clinical...
Betaseron is an investigational small molecule being studied for the treatment of Multiple Sclerosis. It is currently in Phase 2 clinical development. The drug has been evaluated in a completed clinical trial for relapsing-remitting Multiple Sclerosis.
Betaseron is being developed by Bayer AG, a company traded under the ticker BAYRY. The drug is currently in Phase 2 clinical development for Multiple Sclerosis.
Betaseron is in Phase 2 clinical development. It has completed one Phase 2 trial, and there are no active trials currently ongoing. The drug is investigational and has not been approved for any use.
Betaseron has been studied in one completed clinical trial, identified as NCT00893217, titled the BEYOND Pilot Study. This Phase 2 trial enrolled 71 participants with relapsing-remitting Multiple Sclerosis in the United States.
Betaseron is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Multiple Sclerosis. The drug has completed one clinical trial but has not received regulatory approval.